PARIS, June 1 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces today the issuance of 400,000 new shares following the exercise of a tranche of the Paceo line signed between Societe Generale Corporate & Investment Banking (the Bank) and ExonHit Therapeutics in October 2006, and for which prospectus was filed and registered with the Autorite des marches financiers (“AMF”) on October 23, 2006 under number 06-377.
ExonHit Therapeutics has strengthened its shareholders’equity and raised a gross amount of 3,410,480 euros by issuing 400,000 new shares fully subscribed by the Bank. These new shares have been issued at 8.5262 euro per share. This issuance represents 1.5% of the share capital.
About ExonHit Therapeutics
ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.
ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer’disease or atherosclerosis.
In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.
Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris since November 17, 2005.
This press release includes only summary information and does not purport to be comprehensive. The projections, forecast and estimates of ExonHit Therapeutics which may be contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such projections, forecast and estimates involve known and unknown risks and uncertainties, as described at Section 4.2 “Facteurs de risque” (Risk Factors) of the Document de Base available on ExonHit Therapeutics’ website (www.exonhit.com), that may cause actual results, performance or events to differ materially from those anticipated in the summary information.
In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.
Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.
Contacts: ExonHit Therapeutics Bruno Tocque, C.E.O. Philippe Rousseau, C.F.O. Tel: +33-1-58-05-47-00 philippe.rousseau@exonhit.com
ExonHit Therapeutics SA
CONTACT: Contacts: ExonHit Therapeutics, Bruno Tocque, C.E.O., PhilippeRousseau, C.F.O., Tel: +33-1-58-05-47-00, philippe.rousseau@exonhit.com
